Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Guardant Health, Inc. (NASDAQ:GH) have received a consensus rating of “Moderate Buy” from the twenty-three research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and twenty-one have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $106.8571.

Several analysts have weighed in on GH shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research note on Thursday, January 22nd. Barclays lifted their price objective on shares of Guardant Health from $85.00 to $120.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Mizuho set a $135.00 target price on Guardant Health in a research note on Friday, January 9th. Wells Fargo & Company increased their price target on shares of Guardant Health from $93.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Finally, Citigroup raised their price objective on Guardant Health from $100.00 to $135.00 and gave the company a “buy” rating in a report on Thursday, December 11th.

Insider Buying and Selling

In other Guardant Health news, CTO Darya Chudova sold 5,451 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $104.04, for a total transaction of $567,122.04. Following the completion of the sale, the chief technology officer directly owned 7,012 shares in the company, valued at approximately $729,528.48. The trade was a 43.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Terilyn J. Monroe sold 8,571 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $114.09, for a total value of $977,865.39. Following the sale, the insider owned 20,990 shares of the company’s stock, valued at $2,394,749.10. The trade was a 28.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 434,627 shares of company stock worth $45,592,052 in the last quarter. 6.10% of the stock is owned by insiders.

Institutional Trading of Guardant Health

A number of hedge funds and other institutional investors have recently modified their holdings of GH. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health during the fourth quarter valued at about $27,000. Chesapeake Asset Management LLC acquired a new position in Guardant Health during the 4th quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Guardant Health in the 4th quarter valued at about $31,000. IFP Advisors Inc boosted its stake in shares of Guardant Health by 120.1% in the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after buying an additional 334 shares during the period. Finally, Elyxium Wealth LLC acquired a new position in shares of Guardant Health during the fourth quarter worth about $35,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health Trading Up 2.0%

NASDAQ:GH opened at $104.85 on Friday. The company has a market cap of $13.22 billion, a PE ratio of -32.66 and a beta of 1.63. Guardant Health has a twelve month low of $34.88 and a twelve month high of $120.74. The company’s 50 day moving average is $106.38 and its two-hundred day moving average is $83.76.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.